According to the research report titled ‘United States Influenza Vaccines Market: Focus on Persons Vaccinated, Pricing, Production, Supply, Promising Influenza Vaccines, Clinical Trials, Regulatory, Reimbursement, Distribution Channel, Major Deals, Key Players, Recent Developments - Size, Share, Trends, Analysis, Demand, Opportunity, and Forecast, 2022 - 2030’, available with MarketStudyReport, United States influenza vaccines market is expected to expand at 6.9% CAGR, amassing a valuation of USD 7,007 million during 2022-2030.

As per report findings, one of the key factors driving the growth of United States influenza vaccines market is an upsurge in government assistance & monitoring pertaining to the influenza vaccination on the national level to supervise the supply, distribution, and management of flu vaccines.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4751537/  

For those unaware, viral infection induced by the flu in the respiratory system is known as influenza. The influenza virus spreads via respiratory secretions and is extremely contagious. It can also be transmitted from one person to another through conversation or human contact.

The influenza virus rotates indefinitely, causing outbreaks and epidemics that kill thousands of people. The changing nature of the virus necessitates a yearly change in vaccine strain to manage the virus pressure.

Furthermore, increased spending by prominent players in the world, as well as enhanced government funding have fostered the release of therapeutically effective vaccines, propelling United States influenza vaccines industry expansion.

During the coronavirus pandemic, immunization camps and programs run by various healthcare providers were hampered due to strict lockdown policies aimed to control the virus. Having said that, flu vaccination rates reached a peak during the pandemic due to constant nudges by various health professionals and the authorities, who were offering free vaccination to citizens. The fear of the flu and COVID-19 has also heightened awareness.

Moving on, the report enlists the prominent players in United States influenza vaccines marketplace such as EpiVax, Inc., Sanofi Pasteur, Inc., Versatope Therapeutics, Inc., GlaxoSmithKline plc, CSL Limited, FluGen, Inc., Imutex Limited, Altimmune, Inc., Daiichi-Sankyo Company Limited, AstraZeneca plc, Pneumagen Ltd., Novavax, Inc., Moderna, Inc., BiondVax Pharmaceuticals Ltd., and Medicago, Inc. among others.

The document assesses these players based entirely on their earnings, portfolios, and vaccine developmental processes, along with their revenue share. It discusses ongoing trends in the business world like collaborations, mergers and acquisitions, distribution, and licensing agreements.